InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: staccani post# 1524

Saturday, 10/21/2017 1:03:26 PM

Saturday, October 21, 2017 1:03:26 PM

Post# of 2099
"The sponsor has provided preliminary clinical data that demonstrate that treatment improved survival in recurrent platinum-resistant patients. An indirect comparison was conducted to show that the survival benefit compared favourably with the survival observed with authorised products. The Committee considered that this constitutes a clinically relevant advantage.

A positive opinion for ofranergene obadenovec, for treatment of ovarian cancer, was adopted by consensus."

The last part is also a nice read.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News